Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssen's AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1); and collaboration agreement with US Department of Defense for the development of a prophylactic vaccine against the equine encephalitis virus. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:BVNRY
CUSIPN/A
Phone45-3326-8383
Debt
Debt-to-Equity Ratio0.16
Current Ratio11.23
Quick Ratio10.78
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$208.06 million
Price / Sales4.88
Cash Flow$0.3461 per share
Price / Cash30.25
Book Value$3.96 per share
Price / Book2.64
Profitability
EPS (Most Recent Fiscal Year)$0.29
Net Income$27.54 million
Net Margins-0.55%
Return on Equity-0.27%
Return on Assets-0.22%
Miscellaneous
Employees437
Outstanding Shares96,930,000
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions
What is BAVARIAN NORDIC/S's stock symbol?
BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY."
How were BAVARIAN NORDIC/S's earnings last quarter?
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) posted its quarterly earnings data on Thursday, May, 24th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.06. The business earned $1.86 million during the quarter, compared to the consensus estimate of $6.88 million. BAVARIAN NORDIC/S had a negative net margin of 0.55% and a negative return on equity of 0.27%. View BAVARIAN NORDIC/S's Earnings History.
When is BAVARIAN NORDIC/S's next earnings date?
Who are some of BAVARIAN NORDIC/S's key competitors?
Some companies that are related to BAVARIAN NORDIC/S include Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), argenx (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Repligen (RGEN), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO) and Denali Therapeutics (DNLI).
Who are BAVARIAN NORDIC/S's key executives?
BAVARIAN NORDIC/S's management team includes the folowing people:
- Dr. Paul Chaplin MSc, Ph.D., CEO & Pres (Age 51)
- Mr. Ole Larsen, CFO & Exec. VP (Age 53)
- Mr. Henrik Birk MBA, COO & Exec. VP (Age 44)
- Dr. Christopher R. Heery M.D., Chief Medical Officer
- Dr. Tommi Kainu M.D., Ph.D., Exec. VP, Chief Bus. Officer & Member of the Exec. Management (Age 45)
Has BAVARIAN NORDIC/S been receiving favorable news coverage?
Media stories about BVNRY stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BAVARIAN NORDIC/S earned a news sentiment score of 0.03 on Accern's scale. They also gave news stories about the company an impact score of 44.15 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of BAVARIAN NORDIC/S?
Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BAVARIAN NORDIC/S's stock price today?
One share of BVNRY stock can currently be purchased for approximately $10.47.
How big of a company is BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S has a market capitalization of $1.01 billion and generates $208.06 million in revenue each year. The company earns $27.54 million in net income (profit) each year or $0.29 on an earnings per share basis. BAVARIAN NORDIC/S employs 437 workers across the globe.
How can I contact BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected]
MarketBeat Community Rating for BAVARIAN NORDIC/S (BVNRY)
MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote "Outperform" if you believe BVNRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
